Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

Author： Lyman Gary   Lalla Anjana   Barron Richard   Dubois Robert W.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.2, 2009-02, pp. : 401-411

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin’s Lymphoma Patients Receiving Pegfilgrastim

By  

Acta Haematologica, Vol. 125, Iss. 3, 2010-11 ,pp. : 107-114

Karger

Access to resources Recommend Favorite

Second primary cutaneous T‐cell lymphoma in patients with non‐Hodgkin lymphoma: a chicken‐or‐the‐egg issue

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 1, 2018-01 ,pp. : 113-113

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation

By Sánchez-Ortega Isabel  

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 736-743

Informa Healthcare

Access to resources Recommend Favorite

Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R‐CHOP‐14 for elderly patients with diffuse large B‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 787-794

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prospective Randomized Study Comparing MEMID with a Chop-Like Regimen in Elderly Patients with Aggressive Non-Hodgkin’s Lymphoma

By  

Oncology, Vol. 69, Iss. 1, 2005-09 ,pp. : 19-26

Karger

Access to resources Recommend Favorite